FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014734278> ?p ?o ?g. }

• W2014734278 endingPage "158" @default.
• W2014734278 startingPage "157" @default.
• W2014734278 abstract "Introduction Despite the progress made in the management of hypercholesterolemia with statins, events are reduced by only 30% [1••]. Protecting the other 70% requires, additionally, interventions including adjunctive use of anti-inflammatory or immunologic treatments. The results of the statin trials seriously underestimate the ultimate potential of cholesterol-lowering therapy. Experts suggest continuing and more extensive use of lipid-improving regimens and intervention at an earlier stage [1••]. HDL therapy HDL, which is a major target for therapy in CAD, is highly heterogeneous, has a variety of functions that may contribute to its cardiovascular protective effects, including promotion of reverse cholesterol transport (RCT), anti-inflammatory and nitric oxide-promoting effects [2]. Under the inflammatory pressure, however, HDL can become dysfunctional [3]. Normal HDL has high levels of antioxidants and active antioxidant proteins/enzymes and is anti-inflammatory (aiHDL). Proinflammatory HDL (piHDL) has high levels of prooxidant molecules, which interfere with HDL removal of cellular toxic waste and HDL delivery of this metabolic waste for elimination. HDL from individuals with coronary artery disease (CAD) was not able to prevent LDL lipid oxidation [4] and HDL from obese individuals was unable to maintain vascular relaxation [5]. In renal patients, the survival rate for those with aiHDL was four-fold than for those with piHDL [6•]. Women with systemic lupus erythematosus (SLE) have increased risk of coronary artery disease (CAD). McMahon et al. [7] showed that SLE patients had high levels of piHDL, which correlated with the levels of oxidized LDL. SLE patients with CAD had higher piHDL scores than those without CAD. Patients with Crohn's disease had piHDL, which improved upon standard therapy [8]. Among other factors, the failure of torcetrapib has fuelled speculation that in addition to raising HDL-cholesterol, the quality and function of HDL needs to be improved [9]. Statins were shown to improve HDL quality and function in patients with CAD [10]. Patients with rheumatoid arthritis (RA) have increased risk of myocardial infarction. Charles-Schoeman et al. [11•] showed that in a group of patients with active RA, unlike HDL from healthy individuals, HDL from patients with RA was proinflammatory. This piHDL was rendered anti-inflammatory by high-dose atorvastatin [11•]. Novel compounds and approaches Several compounds are being tested in clinical trials including an extended-release niacin, which does not produce flushing and increases HDL–apoA1 and decreases triglycerides and VLDL/LDL [12]; a PPAR-α agonist LY518674, affecting the production and clearance of apoA-I and HDL [13]; the apoA-I mimetic peptide 4F, which was shown to be safe and well tolerated and improved the HDL anti-inflammatory index [4]; and a microsomal triglyceride transfer protein inhibitor (AEGR-733) [14]. In addition, it is recommended [15,16] that efforts be directed toward promotion of RCT and its robust measures. As obesity and metabolic syndrome have become a serious global health issue [17], therapeutic strategies are needed that directly target adipose tissue to optimally reduce cardiometabolic risk. Conclusion Certain lipoproteins and the renin–angiotensin–aldosterone system are important in the pathogenesis of atherosclerotic cardiovascular disease. Understanding how risk factors such as high blood pressure, dysregulated blood lipids and diabetes contribute to atherosclerotic disease, as well as elucidation of the molecular pathogenesis of atherosclerotic plaques, are leading to new targets for therapy [18••]." @default.
• W2014734278 created "2016-06-24" @default.
• W2014734278 creator A5019908632 @default.
• W2014734278 creator A5024253286 @default.
• W2014734278 creator A5028187159 @default.
• W2014734278 creator A5038343851 @default.
• W2014734278 creator A5039925909 @default.
• W2014734278 date "2009-04-01" @default.
• W2014734278 modified "2023-09-24" @default.
• W2014734278 title "Dyslipidemia and cardiovascular diseases" @default.
• W2014734278 cites W1513392978 @default.
• W2014734278 cites W1974455553 @default.
• W2014734278 cites W1994712431 @default.
• W2014734278 cites W2002720021 @default.
• W2014734278 cites W2016645249 @default.
• W2014734278 cites W2042179291 @default.
• W2014734278 cites W2046959088 @default.
• W2014734278 cites W2063023478 @default.
• W2014734278 cites W2095913250 @default.
• W2014734278 cites W2099065288 @default.
• W2014734278 cites W2106526990 @default.
• W2014734278 cites W2109807835 @default.
• W2014734278 cites W2166849509 @default.
• W2014734278 cites W2167034797 @default.
• W2014734278 doi "https://doi.org/10.1097/mol.0b013e32832956ed" @default.
• W2014734278 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19276898" @default.
• W2014734278 hasPublicationYear "2009" @default.
• W2014734278 type Work @default.
• W2014734278 sameAs 2014734278 @default.
• W2014734278 citedByCount "5" @default.
• W2014734278 countsByYear W20147342782014 @default.
• W2014734278 countsByYear W20147342782018 @default.
• W2014734278 countsByYear W20147342782020 @default.
• W2014734278 crossrefType "journal-article" @default.
• W2014734278 hasAuthorship W2014734278A5019908632 @default.
• W2014734278 hasAuthorship W2014734278A5024253286 @default.
• W2014734278 hasAuthorship W2014734278A5028187159 @default.
• W2014734278 hasAuthorship W2014734278A5038343851 @default.
• W2014734278 hasAuthorship W2014734278A5039925909 @default.
• W2014734278 hasBestOaLocation W20147342781 @default.
• W2014734278 hasConcept C126322002 @default.
• W2014734278 hasConcept C134018914 @default.
• W2014734278 hasConcept C164027704 @default.
• W2014734278 hasConcept C2776914184 @default.
• W2014734278 hasConcept C2778096610 @default.
• W2014734278 hasConcept C2778163477 @default.
• W2014734278 hasConcept C2778213512 @default.
• W2014734278 hasConcept C2779134260 @default.
• W2014734278 hasConcept C2780499067 @default.
• W2014734278 hasConcept C71924100 @default.
• W2014734278 hasConceptScore W2014734278C126322002 @default.
• W2014734278 hasConceptScore W2014734278C134018914 @default.
• W2014734278 hasConceptScore W2014734278C164027704 @default.
• W2014734278 hasConceptScore W2014734278C2776914184 @default.
• W2014734278 hasConceptScore W2014734278C2778096610 @default.
• W2014734278 hasConceptScore W2014734278C2778163477 @default.
• W2014734278 hasConceptScore W2014734278C2778213512 @default.
• W2014734278 hasConceptScore W2014734278C2779134260 @default.
• W2014734278 hasConceptScore W2014734278C2780499067 @default.
• W2014734278 hasConceptScore W2014734278C71924100 @default.
• W2014734278 hasIssue "2" @default.
• W2014734278 hasLocation W20147342781 @default.
• W2014734278 hasLocation W20147342782 @default.
• W2014734278 hasLocation W20147342783 @default.
• W2014734278 hasOpenAccess W2014734278 @default.
• W2014734278 hasPrimaryLocation W20147342781 @default.
• W2014734278 hasRelatedWork W1972011552 @default.
• W2014734278 hasRelatedWork W2005998106 @default.
• W2014734278 hasRelatedWork W2023154173 @default.
• W2014734278 hasRelatedWork W2028009073 @default.
• W2014734278 hasRelatedWork W2032958076 @default.
• W2014734278 hasRelatedWork W2035331946 @default.
• W2014734278 hasRelatedWork W2059941456 @default.
• W2014734278 hasRelatedWork W2075372262 @default.
• W2014734278 hasRelatedWork W3038304001 @default.
• W2014734278 hasRelatedWork W628893562 @default.
• W2014734278 hasVolume "20" @default.
• W2014734278 isParatext "false" @default.
• W2014734278 isRetracted "false" @default.
• W2014734278 magId "2014734278" @default.
• W2014734278 workType "article" @default.